Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human CD14+ monocytes from early inflammatory arthritis patients before and after a 5day-and 30day-period of methotrexate treatment

ABSTRACT: Methotrexate (MTX) continues to be the anchor drug for patients with rheumatoid arthritis and psoriatic arthritis (RA and PsA) both as monotherapy as well as in combination with other drugs because of its efficacy, safety, low relative cost and the possibility of individualizing dose and method of administration. Following low-dose administration, MTX typically reaches peak plasma concentrations after 1-2 h, and almost completely disappears from the circulation by 24 h. Cellular uptake of MTX is mediated by the Reduced Folate Carrier. Once internalize, MTX is converted into MTX-polyglutamates (MTX-PG), a process that is catalyzed by folylpolyglutamate synthase (FPGS), which sequentially adds glutamic acid residues to MTX, and is one of the critical factors for the therapeutic action of MTX. We carried out a clinical observational study to evaluate the influence of MTX-PG levels on the molecular inflammatory state of monocytes from arthritis patients and relate to the clinical efficacy of MTX.

ORGANISM(S): Homo sapiens

PROVIDER: GSE279719 | GEO | 2026/04/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human CD14+ monocytes from volunteers before and after a 3 hours, 24 hours and 120 hours-period of methotrexate intake. METOMAC trial

Project description:Arthritis patients receive a weekly low-dose of Methotrexate (MTX) as a first-line disease modifying anti-rheumatic drug. Following low-dose administration, MTX typically reaches peak plasma concentrations after 1-2 hours, and almost completely disappears from the circulation by 24 hours. However, the kinetics of the anti-inflammatory action of MTX in monocytes after the initial dose is unknown.To address this issue, we carried out a phase I clinical trial (METOMAC) in which peripheral blood from 6 healthy donors receiving a single dose of MTX was analyzed at distinct time points after drug intake (3 hours, 24 hours, 120 hours). RNA-seq on monocytes isolated at the distinct timepoints was determined.

2026-04-01 | GSE289101 | GEO

Microarray Analysis of Differentially Expressed Genes in human bronchial cells(BEAS-2B) treated MTX

Project description:Methotrexate (MTX) has been widely used for the treatment of a variety of tumors as well as for inflammatory diseases and rheumatoid arthritis (RA). MTX-induced toxicity has been a serious unpredictable side effect of the treatment and an important clinical problem. Possible causes include allergic, cytotoxic or immunologic reactions to this agent. We examined the consequences of the mechanism of MTX-induced pulmonary toxicity gene expression in BEAS-2B cells, huma bronchial cell line, by microarray. The expression of these genes are potential biomarker of methotrexate-induced pulmonary toxicity. Also, We provide a clue about mechanism of pulmonary toxic action by these clinical chemotherapeutic agents. Keywords: 48h treatment, 0.144uM (dose), MTX

2008-12-06 | GSE9815 | GEO

Remission in Juvenile Idiopathic Arthritis Achieved on Different Drug Regimens

Project description:Remission has become both the gold standard for clinical care and the end point for clinical trials for children with juvenile idiopathic arthritis (JIA). Using gene expression microarrays, we found that when remission induced by methotrexate (MTX) or MTX plus a TNF inhibitor (etanercept, Et) (MTX+Et) was compared with healthy controls, there were notable differences in gene expression patterns, demonstrating that remission is not a restoration of immunologic normalcy. Differences were detected in PBMC as well as in granulocytes. Total RNA was extracted from isolated PBMC and granulocytes from patients with polyarticular JIA and from healthy controls. Patients had achieved remission (clinical remission on medicine as defined by Wallace et al, Arthritis Rheum. 2005;52(11):3354-3562) using either MTX or MTX+Et.

2013-10-24 | E-GEOD-41831 | biostudies-arrayexpress

The predictive biomarkers of TNFα-blocking agent responsiveness are specific for adalimumab and etanercept

Project description:The objective of this study was to identify specific gene expression profiles able to predict the response of rheumatoid arthritis patients treated with methotrexate (MTX)/adalimumab (ADA) or MTX/etanercept (ETA). Twenty RA patients were received subcutaneously Adalimumab (40 mg each other week) and eleven RA patients were received Etanercept (50 mg per week). The drug efficacy was evaluated with the DAS28 score after 3 months of treatment according to the EULAR response criteria. A blood sample was carried out in patients just before the first injection of treatment in order to isolate peripheral blood mononuclear cells (PBMC) and extract total RNA.

2024-03-22 | GSE42842 | GEO

Differential gene expression profile may differentiate responders from non-reponders rheumatoid arthritis patients to methotrexate monotherapy and methotrexate plus TNF-blocker combined therapy

Project description:Oligo microarrays were used to access the transcription profiling of the rheumatoid arthritis patients under two different therapeutic approaches, aiming to evaluate if the cDNA microarray study is able to differentiate responders and non-responders to therapies. In the first experiment (MTX therapy) we analyzed 25 patients from which 8 were classified as MTX responders and 17 MTX non-responders. In the second experiment from the 17 MTX non-responder patients, 8 were non-responders and 9 were responders to additional anti-TNF therapy.

2011-12-31 | E-MEXP-3390 | biostudies-arrayexpress

Methotrexate activates aspects of inflammation in EA.hy 926 cells

Project description:Methotrexate (MTX) is an anti-folate drug used to treat inflammatory diseases such as rheumatoid arthritis. The changes induced by MTX were profiled within EA.hy 926 cells grown in normal (Hi) and low (Lo) folate. Several inflammatory genes were up regulated and several mitosis related genes were down regulated. Hi and Lo cells were grown to confluence and maintained in fresh medium for 24 hours prior to treatment with 0.5uM MTX for 48 hours.

2012-09-30 | E-GEOD-32008 | biostudies-arrayexpress

Hepatoprotective Effect of Nitrate Against Methotrexate-Induced Liver Injury by Activating Wnt/β-Catenin Signaling in Mice

Project description:Methotrexate (MTX) is an effectively used drug for certain forms of cancer and autoimmune diseases. However, its hepatotoxicity severely limits its clinical use which has no effective treatment but withdrawal. Therefore, further study is required to combat the liver injury associated with MTX. Nitrate, abundant in green vegetables, possesses diverse physiological roles including anti-inflammatory, antioxidant, and immunoregulation. This study investigated the preventive effect of nitrate on MTX-induced liver injury. The liver injury model in mice was induced by a single dose of MTX (20 mg/kg) injected intraperitoneally (i.p.). Administration of 2 mM nitrate in drinking water 5 days prior effectively mitigated MTX-elevated serum aminotransferases, attenuated hepatic pathological injury, reduced the level of hepatic apoptosis, and restored the proliferative capacity of hepatocytes. The molecular mechanism may involve the activation of the Wnt/β-catenin pathway. In this study, the hepatoprotective effect of nitrate on drug-induced liver injury (DILI) was identified for the first time, which provides a new idea for the prevention of drug-induced liver injury in clinical practice.

2025-08-06 | GSE272407 | GEO

Methotrexate activates aspects of inflammation in EA.hy 926 cells

2012-09-30 | GSE32008 | GEO

Remission in Juvenile Idiopathic Arthritis Achieved on Different Drug Regimens

2013-10-24 | GSE41831 | GEO

Epigenome wide association study of response to methotrexate in early rheumatoid arthritis patients

Project description:The aim of the study is to identify differentially methylated positions (DMPs) and regions (DMRs) that predict response to Methotrexate (MTX) in early rheumatoid arthritis (RA) patients. DNA from baseline peripheral blood mononuclear cells was extracted from treatment naive RA patients. DNA methylation, quantified using the Infinium MethylationEPIC, was assessed in relation to response to MTX (combination) therapy (deltaDAS28) over the first 3 months in 69 RA patients.

2021-02-07 | E-MTAB-10159 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data